Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Lotem

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Cancer Immunology Research|March 25, 2021
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector FunctionsEmma Hajaj, Elad Zisman, Shay Tzaban, et al.
Nature Communications|February 16, 2020
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanomaShelly Kalaora, Joo Sang Lee, Eilon Barnea, et al.
Medicine|May 18, 2017
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsAviad Zick, Tamar Peretz, Michal Lotem, et al.
Nature Biomedical Engineering|June 29, 2026
The evolving role of cytokines for CAR-T cell manufacturing and beyondMar Guaza-Lasheras, Johanna Nimmerfroh, Dominic Schwarz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 5, 2021
<i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironmentMartino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj, et al.
BMC Cancer|May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE studyStéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Journal of Immunology Research|June 14, 2016
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 BlockadeMichal Lotem, Sharon Merims, Stephen Frank, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Cancer Immunology Research|March 25, 2021
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector FunctionsEmma Hajaj, Elad Zisman, Shay Tzaban, et al.
Nature Communications|February 16, 2020
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanomaShelly Kalaora, Joo Sang Lee, Eilon Barnea, et al.
Medicine|May 18, 2017
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsAviad Zick, Tamar Peretz, Michal Lotem, et al.
Nature Biomedical Engineering|June 29, 2026
The evolving role of cytokines for CAR-T cell manufacturing and beyondMar Guaza-Lasheras, Johanna Nimmerfroh, Dominic Schwarz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 5, 2021
<i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironmentMartino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj, et al.
BMC Cancer|May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE studyStéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Journal of Immunology Research|June 14, 2016
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 BlockadeMichal Lotem, Sharon Merims, Stephen Frank, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Pageof 10